Buy Or Sell Opportunity • Jul 06
Now 23% undervalued Over the last 90 days, the stock has risen 21% to ₹1,577. The fair value is estimated to be ₹2,041, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.6% over the last 3 years. Earnings per share has grown by 33%. Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,631, the stock trades at a trailing P/E ratio of 28.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 214% over the past three years. Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹1,351, the stock trades at a trailing P/E ratio of 24.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 158% over the past three years. Buy Or Sell Opportunity • Jun 02
Now 26% undervalued Over the last 90 days, the stock has risen 17% to ₹1,521. The fair value is estimated to be ₹2,059, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.7% over the last 3 years. Earnings per share has grown by 33%. Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹57.26 (vs ₹66.51 in FY 2025) Full year 2026 results: EPS: ₹57.26 (down from ₹66.51 in FY 2025). Revenue: ₹3.36b (down 2.5% from FY 2025). Net income: ₹173.1m (down 14% from FY 2025). Profit margin: 5.1% (down from 5.8% in FY 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 29
Haleos Labs Limited Recommends Dividend for the Year 2025-26 Haleos Labs Limited recommended dividend of INR 1.50/- (15%) per equity share of INR 10/- face value, for the year 2025-26, subject to the approval of the Shareholders at the presenting 20th Annual General Meeting of the Company. Announcement • May 22
Haleos Labs Limited to Report Q4, 2026 Results on May 29, 2026 Haleos Labs Limited announced that they will report Q4, 2026 results on May 29, 2026 New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹4.86b market cap, or US$50.2m). Buy Or Sell Opportunity • Mar 25
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.7% to ₹1,238. The fair value is estimated to be ₹1,612, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Earnings per share has grown by 27%. Reported Earnings • Feb 13
Third quarter 2026 earnings released: EPS: ₹21.89 (vs ₹18.08 in 3Q 2025) Third quarter 2026 results: EPS: ₹21.89 (up from ₹18.08 in 3Q 2025). Revenue: ₹949.7m (up 12% from 3Q 2025). Net income: ₹66.2m (up 21% from 3Q 2025). Profit margin: 7.0% (up from 6.5% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 04
Haleos Labs Limited to Report Q3, 2026 Results on Feb 11, 2026 Haleos Labs Limited announced that they will report Q3, 2026 results on Feb 11, 2026 New Risk • Jan 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (₹3.91b market cap, or US$43.3m). Reported Earnings • Nov 11
Second quarter 2026 earnings released: EPS: ₹20.19 (vs ₹15.46 in 2Q 2025) Second quarter 2026 results: EPS: ₹20.19 (up from ₹15.46 in 2Q 2025). Revenue: ₹817.9m (up 4.2% from 2Q 2025). Net income: ₹61.0m (up 31% from 2Q 2025). Profit margin: 7.5% (up from 6.0% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 24% per year. Announcement • Nov 04
Haleos Labs Limited to Report Q2, 2026 Results on Nov 10, 2025 Haleos Labs Limited announced that they will report Q2, 2026 results on Nov 10, 2025 Upcoming Dividend • Sep 17
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 24 September 2025. Payment date: 30 October 2025. Payout ratio is a comfortable 2.3% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.7%). Declared Dividend • Aug 28
Dividend of ₹1.50 announced Dividend of ₹1.50 is the same as last year. Ex-date: 24th September 2025 Payment date: 30th October 2025 Dividend yield will be 0.1%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (2% earnings payout ratio) and cash flows (2% cash payout ratio). The dividend has remained flat since 6 years ago. However, payments have been volatile during that time. Earnings per share has grown by 17% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Aug 27
Haleos Labs Limited announces Annual dividend, payable on October 30, 2025 Haleos Labs Limited announced Annual dividend of INR 1.5000 per share payable on October 30, 2025, ex-date on September 24, 2025 and record date on September 24, 2025. New Risk • Aug 13
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 40% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (40% net debt to equity). Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (₹3.33b market cap, or US$38.1m). Reported Earnings • Aug 12
First quarter 2026 earnings released: EPS: ₹13.75 (vs ₹23.15 in 1Q 2025) First quarter 2026 results: EPS: ₹13.75 (down from ₹23.15 in 1Q 2025). Revenue: ₹835.0m (down 9.8% from 1Q 2025). Net income: ₹41.6m (down 41% from 1Q 2025). Profit margin: 5.0% (down from 7.6% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Aug 11
SMS Lifesciences India Limited, Annual General Meeting, Sep 30, 2025 SMS Lifesciences India Limited, Annual General Meeting, Sep 30, 2025. Announcement • Aug 09
SMS Lifesciences India Limited to Report Q1, 2026 Results on Aug 11, 2025 SMS Lifesciences India Limited announced that they will report Q1, 2026 results on Aug 11, 2025 Reported Earnings • May 30
Full year 2025 earnings released: EPS: ₹66.51 (vs ₹30.08 in FY 2024) Full year 2025 results: EPS: ₹66.51 (up from ₹30.08 in FY 2024). Revenue: ₹3.50b (up 14% from FY 2024). Net income: ₹201.1m (up 121% from FY 2024). Profit margin: 5.8% (up from 3.0% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Announcement • May 22
SMS Lifesciences India Limited to Report Q4, 2025 Results on May 29, 2025 SMS Lifesciences India Limited announced that they will report Q4, 2025 results on May 29, 2025 Valuation Update With 7 Day Price Move • May 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹1,457, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 139% over the past three years. New Risk • Apr 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (45% net debt to equity). Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹3.43b market cap, or US$40.0m). Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,272, the stock trades at a trailing P/E ratio of 16.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 82% over the past three years. Reported Earnings • Feb 14
Third quarter 2025 earnings released: EPS: ₹18.08 (vs ₹14.24 in 3Q 2024) Third quarter 2025 results: EPS: ₹18.08 (up from ₹14.24 in 3Q 2024). Revenue: ₹846.6m (up 18% from 3Q 2024). Net income: ₹54.7m (up 27% from 3Q 2024). Profit margin: 6.5% (up from 6.0% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings. Announcement • Feb 07
SMS Lifesciences India Limited to Report Q3, 2025 Results on Feb 12, 2025 SMS Lifesciences India Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 1 highly experienced director. Non-Executive Independent Director Mannam Malakondaiah was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹1,223, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 43% over the past three years. Reported Earnings • Nov 15
Second quarter 2025 earnings released: EPS: ₹15.46 (vs ₹2.20 in 2Q 2024) Second quarter 2025 results: EPS: ₹15.46 (up from ₹2.20 in 2Q 2024). Revenue: ₹805.0m (up 16% from 2Q 2024). Net income: ₹46.7m (up ₹40.1m from 2Q 2024). Profit margin: 5.8% (up from 1.0% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹1,158, the stock trades at a trailing P/E ratio of 19.6x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 38% over the past three years. Announcement • Nov 09
SMS Lifesciences India Limited to Report Q2, 2025 Results on Nov 13, 2024 SMS Lifesciences India Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Valuation Update With 7 Day Price Move • Oct 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹1,368, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 39x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past three years. Upcoming Dividend • Sep 16
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 23 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 5.0% and this is well supported by cash flows. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.0%). Lower than average of industry peers (0.6%). Valuation Update With 7 Day Price Move • Sep 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹1,665, the stock trades at a trailing P/E ratio of 28.2x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 130% over the past three years. Declared Dividend • Aug 28
Dividend of ₹1.50 announced Dividend of ₹1.50 is the same as last year. Ex-date: 23rd September 2024 Payment date: 30th October 2024 Dividend yield will be 0.1%, which is lower than the industry average of 0.8%. Payout Ratios Payout ratio: 5%. Cash payout ratio: 13%. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,302, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 76% over the past three years. Reported Earnings • Aug 10
First quarter 2025 earnings released: EPS: ₹23.15 (vs ₹5.94 loss in 1Q 2024) First quarter 2025 results: EPS: ₹23.15 (up from ₹5.94 loss in 1Q 2024). Revenue: ₹929.9m (up 25% from 1Q 2024). Net income: ₹70.0m (up ₹87.9m from 1Q 2024). Profit margin: 7.5% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Announcement • Aug 09
SMS Lifesciences India Limited, Annual General Meeting, Sep 30, 2024 SMS Lifesciences India Limited, Annual General Meeting, Sep 30, 2024. Announcement • Aug 06
SMS Lifesciences India Limited to Report Q1, 2025 Results on Aug 09, 2024 SMS Lifesciences India Limited announced that they will report Q1, 2025 results on Aug 09, 2024 Recent Insider Transactions • Jul 04
Board Member recently bought ₹5.3m worth of stock On the 28th of June, Talluri Praveen bought around 6k shares on-market at roughly ₹827 per share. This transaction amounted to 5.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹21m more in shares than they have sold in the last 12 months. New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.9x net interest cover). Earnings have declined by 5.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.7% net profit margin). Market cap is less than US$100m (₹2.53b market cap, or US$30.4m). Valuation Update With 7 Day Price Move • May 28
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹821, the stock trades at a trailing P/E ratio of 51.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 38% over the past three years. Announcement • May 23
SMS Lifesciences India Limited to Report Q4, 2024 Results on May 27, 2024 SMS Lifesciences India Limited announced that they will report Q4, 2024 results on May 27, 2024 Recent Insider Transactions • Apr 02
Board Member recently bought ₹10.0m worth of stock On the 28th of March, Talluri Praveen bought around 15k shares on-market at roughly ₹645 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹15m more in shares than they have sold in the last 12 months. Reported Earnings • Feb 11
Third quarter 2024 earnings released: EPS: ₹14.24 (vs ₹13.18 in 3Q 2023) Third quarter 2024 results: EPS: ₹14.24 (up from ₹13.18 in 3Q 2023). Revenue: ₹726.4m (down 18% from 3Q 2023). Net income: ₹43.0m (up 8.0% from 3Q 2023). Profit margin: 5.9% (up from 4.5% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Feb 03
SMS Lifesciences India Limited to Report Q3, 2024 Results on Feb 10, 2024 SMS Lifesciences India Limited announced that they will report Q3, 2024 results at 4:00 PM, Indian Standard Time on Feb 10, 2024 Reported Earnings • Nov 13
Second quarter 2024 earnings released: EPS: ₹2.20 (vs ₹10.33 in 2Q 2023) Second quarter 2024 results: EPS: ₹2.20 (down from ₹10.33 in 2Q 2023). Revenue: ₹696.0m (down 14% from 2Q 2023). Net income: ₹6.66m (down 76% from 2Q 2023). Profit margin: 1.0% (down from 3.4% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 6% per year whereas the company’s share price has fallen by 5% per year. Announcement • Nov 05
SMS Lifesciences India Limited to Report Q2, 2024 Results on Nov 11, 2023 SMS Lifesciences India Limited announced that they will report Q2, 2024 results at 4:00 PM, Indian Standard Time on Nov 11, 2023 Upcoming Dividend • Sep 15
Upcoming dividend of ₹1.50 per share at 0.3% yield Eligible shareholders must have bought the stock before 22 September 2023. Payment date: 29 October 2023. Payout ratio is a comfortable 4.0% but the company is not cash flow positive. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.9%). Announcement • Aug 09
SMS Lifesciences India Limited, Annual General Meeting, Sep 29, 2023 SMS Lifesciences India Limited, Annual General Meeting, Sep 29, 2023. New Risk • Aug 09
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.5x net interest cover). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.2% net profit margin). Market cap is less than US$100m (₹1.55b market cap, or US$18.7m). Reported Earnings • Aug 09
First quarter 2024 earnings released: ₹5.94 loss per share (vs ₹9.95 profit in 1Q 2023) First quarter 2024 results: ₹5.94 loss per share (down from ₹9.95 profit in 1Q 2023). Revenue: ₹752.7m (down 8.5% from 1Q 2023). Net loss: ₹18.0m (down 160% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 6% per year. Announcement • Aug 03
SMS Lifesciences India Limited to Report Q1, 2024 Results on Aug 08, 2023 SMS Lifesciences India Limited announced that they will report Q1, 2024 results on Aug 08, 2023 Announcement • May 31
SMS Lifesciences India Limited Recommends Dividend for the Year 2022-23 SMS Lifesciences India Limited recommended a dividend of INR 1.50 per equity share of INR 10 face value, for the year 2022-23, subject to the approval of the Shareholders a the upcoming Annual General Meeting of the Company. Reported Earnings • May 31
Full year 2023 earnings released: EPS: ₹37.92 (vs ₹83.76 in FY 2022) Full year 2023 results: EPS: ₹37.92 (down from ₹83.76 in FY 2022). Revenue: ₹3.19b (down 8.9% from FY 2022). Net income: ₹114.6m (down 55% from FY 2022). Profit margin: 3.6% (down from 7.2% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 24% per year and the company’s share price has also increased by 24% per year. Announcement • May 23
SMS Lifesciences India Limited to Report Q4, 2023 Results on May 29, 2023 SMS Lifesciences India Limited announced that they will report Q4, 2023 results at 4:00 PM, Indian Standard Time on May 29, 2023 Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹13.18 (vs ₹7.70 in 3Q 2022) Third quarter 2023 results: EPS: ₹13.18 (up from ₹7.70 in 3Q 2022). Revenue: ₹882.9m (down 3.0% from 3Q 2022). Net income: ₹39.9m (up 71% from 3Q 2022). Profit margin: 4.5% (up from 2.6% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 25% per year, which means it is significantly lagging earnings growth. Announcement • Feb 11
SMS Lifesciences India Limited Announces Resignation of Venkafasubbarao Polluri as Independent Director from the Board and Member of Audit Committee SMS Lifesciences India Limited announced that Mr. Venkafasubbarao Polluri dated February 10. 2023. resigned as Independent Director from the Board of the Company with immediate effect on account of personal reasons. He also ceased to be a member of the Audit Committee of the Company. Announcement • Feb 04
SMS Lifesciences India Limited to Report Q3, 2023 Results on Feb 10, 2023 SMS Lifesciences India Limited announced that they will report Q3, 2023 results on Feb 10, 2023 Reported Earnings • Nov 19
Second quarter 2023 earnings released: EPS: ₹10.33 (vs ₹33.91 in 2Q 2022) Second quarter 2023 results: EPS: ₹10.33 (down from ₹33.91 in 2Q 2022). Revenue: ₹814.1m (down 6.2% from 2Q 2022). Net income: ₹27.5m (down 73% from 2Q 2022). Profit margin: 3.4% (down from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 30% per year, which means it is significantly lagging earnings growth. Announcement • Oct 02
SMS Lifesciences India Limited Approves Dividend for the Year 2021-2022 SMS Lifesciences India Limited announced that at its AGM held on 30 September 2022, the shareholders approved dividend on equity shares at INR 1.50 per equity share of face value of INR 10 each (15%) for the year 2021-2022. Upcoming Dividend • Sep 15
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 22 September 2022. Payment date: 30 October 2022. Payout ratio is a comfortable 1.8% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.0%). Announcement • Sep 09
SMS Lifesciences India Limited Proposes Dividend for Year 2021-22 The 16th Annual General Meeting (AGM) of the members of SMS Lifesciences India Limited to be held on 30th September, 2022, proposed to declare Dividend on Equity Shares at INR 1.50 per Equity Share of the face value of INR 10 each (15%), for the year 2021-22. Dividend, if declared, at the 16th AGM, will be paid within 30 days by way of credit to the respective Bank accounts of the members from the date of approval by the Shareholders, subject to deduction of tax at source, to those members whose names appear on the register of members of the Company as of end of 23rd September, 2022 ("Record Date"). Reported Earnings • Aug 11
First quarter 2023 earnings released: EPS: ₹9.95 (vs ₹12.00 in 1Q 2022) First quarter 2023 results: EPS: ₹9.95 (down from ₹12.00 in 1Q 2022). Revenue: ₹825.8m (up 8.3% from 1Q 2022). Net income: ₹16.3m (down 55% from 1Q 2022). Profit margin: 2.0% (down from 4.8% in 1Q 2022). Announcement • Aug 10
SMS Lifesciences India Limited, Annual General Meeting, Sep 30, 2022 SMS Lifesciences India Limited, Annual General Meeting, Sep 30, 2022. Recent Insider Transactions • Jun 25
Board Member recently bought ₹16m worth of stock On the 21st of June, Talluri Praveen bought around 23k shares on-market at roughly ₹705 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹30m more in shares than they have sold in the last 12 months. Reported Earnings • May 30
Full year 2022 earnings released: EPS: ₹83.68 (vs ₹44.84 in FY 2021) Full year 2022 results: EPS: ₹83.68 (up from ₹44.84 in FY 2021). Revenue: ₹3.52b (up 33% from FY 2021). Net income: ₹252.8m (up 87% from FY 2021). Profit margin: 7.2% (up from 5.1% in FY 2021). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • May 22
SMS Lifesciences India Limited to Report Q4, 2022 Results on May 28, 2022 SMS Lifesciences India Limited announced that they will report Q4, 2022 results on May 28, 2022 Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improved over the past week After last week's 20% share price gain to ₹875, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 46% over the past three years. Recent Insider Transactions • Apr 03
Insider recently bought ₹4.8m worth of stock On the 31st of March, Annapurna Talluri bought around 7k shares on-market at roughly ₹700 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹1.5m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 13
Insider recently bought ₹1.8m worth of stock On the 9th of March, Gopineedi Sudeepthi bought around 3k shares on-market at roughly ₹675 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold ₹3.3m more in shares than they bought in the last 12 months. Recent Insider Transactions • Feb 28
Board Member recently bought ₹16m worth of stock On the 24th of February, Talluri Praveen bought around 22k shares on-market at roughly ₹728 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹16m more in shares than they have sold in the last 12 months. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹7.70 (down from ₹8.92 in 3Q 2021). Revenue: ₹910.9m (up 37% from 3Q 2021). Net income: ₹23.3m (down 14% from 3Q 2021). Profit margin: 2.6% (down from 4.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Dec 01
Chemwerth, Inc. acquired 10% stake in Mahi Drugs Private Limited from SMS Lifesciences India Limited (NSEI:SMSLIFE). Chemwerth, Inc. acquired 10% stake in Mahi Drugs Private Limited from SMS Lifesciences India Limited (NSEI:SMSLIFE) on November 30, 2021. The deal is subject to approval from SMS Lifesciences India Limited board. As of November 30, 2021 SMS Lifesciences India Limited board approved the deal.
Chemwerth, Inc. completed the acquisition of 10% stake in Mahi Drugs Private Limited from SMS Lifesciences India Limited (NSEI:SMSLIFE) on November 30, 2021. Recent Insider Transactions • Nov 03
Insider recently sold ₹1.7m worth of stock On the 28th of October, Hari Potluri sold around 2k shares on-market at roughly ₹998 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹107m more than they sold in the last 12 months. Valuation Update With 7 Day Price Move • Oct 28
Investor sentiment improved over the past week After last week's 26% share price gain to ₹999, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 151% over the past three years. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment improved over the past week After last week's 17% share price gain to ₹822, the stock trades at a trailing P/E ratio of 15.2x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 126% over the past three years. Upcoming Dividend • Sep 13
Upcoming dividend of ₹1.50 per share Eligible shareholders must have bought the stock before 20 September 2021. Payment date: 30 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.8%). Executive Departure • Sep 06
Non-Executive & Independent Director Neelaveni Thummala has left the company On the 2nd of September, Neelaveni Thummala's tenure as Non-Executive & Independent Director ended after 4.3 years in the role. We don't have any record of a personal shareholding under Neelaveni's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.25 years. Recent Insider Transactions • Jul 01
Insider recently sold ₹2.3m worth of stock On the 23rd of June, Hari Potluri sold around 3k shares on-market at roughly ₹779 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹105m more than they sold in the last 12 months. Executive Departure • Jun 29
Non-Executive Director Ramesh Potluri has left the company On the 18th of June, Ramesh Potluri's tenure as Non-Executive Director ended after 5.2 years in the role. As of March 2021, Ramesh still personally held 245.34k shares (₹121m worth at the time). Ramesh is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 4.00 years. Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment improved over the past week After last week's 16% share price gain to ₹732, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 24x in the Pharmaceuticals industry in India. Total returns to shareholders of 136% over the past three years. Reported Earnings • Jun 20
Full year 2021 earnings released: EPS ₹44.84 (vs ₹33.68 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹2.67b (up 2.5% from FY 2020). Net income: ₹135.6m (up 33% from FY 2020). Profit margin: 5.1% (up from 3.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Apr 23
Investor sentiment improved over the past week After last week's 19% share price gain to ₹643, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 55% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 25% share price gain to ₹618, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 18x in the Pharmaceuticals industry in India. Total returns to shareholders of 52% over the past three years. Is New 90 Day High Low • Feb 22
New 90-day low: ₹538 The company is down 10.0% from its price of ₹598 on 24 November 2020. The Indian market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Reported Earnings • Feb 13
Third quarter 2021 earnings released: EPS ₹8.92 (vs ₹1.12 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹671.8m (up 44% from 3Q 2020). Net income: ₹27.0m (up ₹30.3m from 3Q 2020). Profit margin: 4.0% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Announcement • Feb 08
SMS Lifesciences India Limited to Report Q3, 2021 Results on Feb 12, 2021 SMS Lifesciences India Limited announced that they will report Q3, 2021 results on Feb 12, 2021 Is New 90 Day High Low • Jan 28
New 90-day low: ₹540 The company is down 8.0% from its price of ₹589 on 30 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Recent Insider Transactions • Dec 13
MD & Executive Director recently bought ₹57m worth of stock On the 8th of December, Talluri Veera Venkata Murthy bought around 87k shares on-market at roughly ₹651 per share. This was the largest purchase by an insider in the last 3 months. Talluri Veera Venkata has been a buyer over the last 12 months, purchasing a net total of ₹108m worth in shares. Valuation Update With 7 Day Price Move • Dec 07
Market bids up stock over the past week After last week's 18% share price gain to ₹693, the stock is trading at a trailing P/E ratio of 26.2x, up from the previous P/E ratio of 22.2x. This compares to an average P/E of 23x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 63%. Is New 90 Day High Low • Dec 07
New 90-day high: ₹693 The company is up 55% from its price of ₹447 on 08 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 9.0% over the same period. Recent Insider Transactions • Nov 27
MD & Executive Director recently bought ₹51m worth of stock On the 25th of November, Talluri Veera Venkata Murthy bought around 85k shares on-market at roughly ₹605 per share. This was the largest purchase by an insider in the last 3 months. This was Talluri Veera Venkata's only on-market trade for the last 12 months. Valuation Update With 7 Day Price Move • Nov 11
Market bids up stock over the past week After last week's 16% share price gain to ₹643, the stock is trading at a trailing P/E ratio of 22.5x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 48%. Announcement • Nov 07
SMS Lifesciences India Limited to Report Q2, 2021 Results on Nov 13, 2020 SMS Lifesciences India Limited announced that they will report Q2, 2021 results on Nov 13, 2020 Is New 90 Day High Low • Oct 19
New 90-day high: ₹667 The company is up 97% from its price of ₹339 on 21 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. 
